KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Co-Diagnostics (CODX) EBIT Margin (2017 - 2025)

Historic EBIT Margin for Co-Diagnostics (CODX) over the last 9 years, with Q3 2025 value amounting to 4824.49%.

  • Co-Diagnostics' EBIT Margin fell 32281300.0% to 4824.49% in Q3 2025 from the same period last year, while for Sep 2025 it was 6995.7%, marking a year-over-year decrease of 64493300.0%. This contributed to the annual value of 1023.75% for FY2024, which is 3968200.0% down from last year.
  • Per Co-Diagnostics' latest filing, its EBIT Margin stood at 4824.49% for Q3 2025, which was down 32281300.0% from 4946.14% recorded in Q2 2025.
  • In the past 5 years, Co-Diagnostics' EBIT Margin ranged from a high of 51.61% in Q1 2021 and a low of 17009.68% during Q1 2025
  • Its 5-year average for EBIT Margin is 2583.5%, with a median of 363.68% in 2023.
  • Its EBIT Margin has fluctuated over the past 5 years, first surged by 57746700bps in 2024, then tumbled by -148168200bps in 2025.
  • Over the past 5 years, Co-Diagnostics' EBIT Margin (Quarter) stood at 50.53% in 2021, then plummeted by -3789bps to 1863.84% in 2022, then surged by 82bps to 332.62% in 2023, then plummeted by -2297bps to 7973.9% in 2024, then surged by 39bps to 4824.49% in 2025.
  • Its EBIT Margin stands at 4824.49% for Q3 2025, versus 4946.14% for Q2 2025 and 17009.68% for Q1 2025.